Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM

Clinical trial NCT03311945 · COMPLETED

Trial details

NCT number: NCT03311945
Sponsor: Judit Pich
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

HIV Infections HIV-1-infection HIV Seropositivity

Start date: 2018-05-02
Primary completion: 2021-03-30
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.